NCT04222413View on ClinicalTrials.gov

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Advanced Solid TumorsMetastatic Pancreatic CancerPediatric Solid TumorAdvanced Breast CancerMalignant Peripheral Nerve Sheath TumorColorectal Neoplasms
Interventions
DRUG

Metarrestin

Phase IA: Loading dose on Day 1 of Cycle 1 for Dose Levels 1-7. Loading dose on Days 1 and 3 of Cycle 1 for Dose Levels 8-11. After the loading dose on Day 1 or Days 1 and 3 of Cycle 1, continue on Mondays-Wednesdays-Fridays of every following cycle. Phase IB: PO according to the dose and schedule estimated during Phase IA

Trial Locations (2)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

66205

RECRUITING

University of Kansas, Fairway

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH